Need advice in managing cancer immunotherapy cardiotoxicity?

Request Assistance

FDA Public Workshop: Assessment of Cardiovascular Toxicities in Immuno-oncology Trials
Posted by Moslehi on January 22, 2018

On Friday, December 1, 2017, the U.S. Food & Drug Administration (FDA) announced a public workshop entitled, “Assessment of Cardiovascular Toxicities in Immuno-oncology Trials”. This workshop provided a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. The workshop focused on the identification...

Read More
Manuscripts published in Circulation raise awareness for immune checkpoint inhibitor associated myocarditis
Posted by Moslehi on January 22, 2018

Two manuscripts published on November 21, 2017 of the journal Circulation bring additional awareness for the syndrome of immune checkpoint-inhibitor (ICI)-associated myocarditis. Thuny and colleagues (Hospital Nord, Marseille, France) present a case series of 30 patients with ICI-induced cardiotoxicity. Cardiotoxicity was diagnosed at a...

Read More
Cardio-Oncology highlighted at American Heart Association Annual Meeting 2017
Posted by Moslehi on January 22, 2018

There were several cardio-oncology sessions at the American Heart Association (AHA) annual meeting which occurred in November 2017 in Anaheim, California. A session called “The Emerging Science of Cardio-Oncology” focused on the rapidly evolving area of clinical practice in cancer patients with heart failure or acute coronary...

Read More
View All
connect with us

Announcing the creation of @UCSF Myocarditis Center! Hoping to bring better mechanistic understanding of the disease to help our patients! @DrJESalem @ImmunoCardioLab @ACCinTouch @HeartNews @NatureCVR @PilarMartinFern @CircAHA @CircRes #CardioImmunology

Exited 2 have @vnparikh for @UCSFCardiology Grand Rounds tomorrow! @SarnoffCardio @StanCVFellows @jpirruccello @UCSF_CVfellows @StanCVFellows @KMAlexanderMD @StanfordCVI

Looking forward to the UCSF ImmunoX talk by @jccarnevale today. Great demonstration by the power of CRISPR engineering in T cells? Can we apply this technology to cardiovascular disease? UCSF the best place to find out! @MarsonLab @vnparikh @ImmunobiologySG @UCSFCardiology

Plasmapheresis to treat immune-checkpoint T-cells mediated life-threatening adverse event ? Nop😟
PD(L)1 receptor occupancy on T-cells is completely blocked for monthes with anti-PD(L)1 blood levels >>>IC50 for months even after pheresis-for more details👇